Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G. Attia S, et al. Among authors: mulkerin dl. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51. doi: 10.1007/s00280-008-0844-1. Epub 2008 Oct 8. Cancer Chemother Pharmacol. 2009. PMID: 18841362 Free PMC article. Clinical Trial.
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. Mulkerin D, et al. Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8. Invest New Drugs. 2009. PMID: 19129971 Free PMC article. Clinical Trial.
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. LoConte NK, et al. Among authors: mulkerin dl. Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21. Invest New Drugs. 2013. PMID: 23263993 Free PMC article. Clinical Trial.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. LoConte NK, et al. Among authors: mulkerin dl. Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17. Invest New Drugs. 2015. PMID: 25318436 Free PMC article. Clinical Trial.
56 results